NCT00008697View on ClinicalTrials.gov

Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

April 30, 2002

Study Completion Date

April 30, 2002

Conditions
Leukemia
Interventions
DRUG

arsenic trioxide

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Washington University School of Medicine

OTHER

NCT00008697 - Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia | Biotech Hunter | Biotech Hunter